NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today outlined its strategic priorities and key catalysts expected for 2026. “2025 was a transformational year for Cellectis, as we transitioned to a late-stage development allogeneic CAR-T company with the initiation of a pivotal Phase 2 trial for lasme-cel.

Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with advanced dry macular degeneration. The hair-thin patch replaces damaged retinal cells responsible for sharp, central vision. Earlier studies showed the implant was safe and helped some patients see better. Researchers now hope it can deliver meaningful, lasting improvements in eyesight.Age-related macular degeneration is the most common cause of vision loss and blindness among Am

A large genetic study shows that many people carry DNA sequences that slowly expand as they get older. Common genetic variants can dramatically alter how fast this expansion happens, sometimes multiplying the pace by four. Researchers also identified specific DNA expansions linked to severe kidney and liver disease. The findings suggest that age-related DNA instability is far more common than previously realized.A large scale genetic analysis of more than 900,000 people has revealed that specifi

MENLO PARK, CA, Jan. 9, 2026 – Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the completion of a Series F financing round in December 2025 led by Lightspeed Venture Partners. With $250M in new equity capital from its two most recent financing rounds, along with a 2025 amendment to its Silicon Valley Bank credit facility providing up to $100M in additional liquidity, Orca Bio possesses the financia

GAITHERSBURG, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced it has received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax ® (Anthrax Vaccine Adsorbed) in 2026. This order is under Emergent’s existing indefinite-delivery/indefinite-quantity (IDIQ) contract (W911SR24D0001), led by the Capability Program Executive Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), previously the Joint

SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- MediLink Therapeutics ("MediLink") today announced that it has entered into a new collaboration and exclusive licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the development and commercialization of YL201, an investigational novel antibody-drug conjugate (ADC) asset targeting B7H3 across numerous solid tumor types. Under the terms of the agreement, MediLink will grant Roche an exclusive license to develop, manufacture, and commercializ

iStock, hapabapa Roche first partnered with MediLink in January 2024, likewise for an antibody-drug conjugate for solid tumors. Roche once again tapped its Chinese partner MediLink for another antibody-drug conjugate to be studied across several solid tumor types, nearly two years to the day after first partnering. Roche is offering $570 million in upfront and near-term milestone payments to get exclusive rights to MediLink’s YL201, a B7H3-targeted therapy, according to news release on Thursda

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided additional context regarding its previously announced proposal to change the Company’s jurisdiction of incorporation from Alberta, Canada, to the State of Nevada in the United States. The Company believes it is important to clearly communicate the strategic and operational reasons underlying this proposal

PRESS RELEASE Memo Therapeutics AG Publishes BKPyV Infection Disease Burden Study in the Journal of Patient-Reported Outcomes First conceptual model demonstrating the impact of BK polyomavirus on the health-related quality of life of kidney transplant recipients Study conducted in partnership with Northwestern University and presented at the World Transplant Congress in August 2025 Schlieren / Zurich, Switzerland, 9 January, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company tr

TOLEDO, Ohio , Jan. 8, 2026 /PRNewswire/ -- NAMSA , a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE: LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide. As